Ferrol

• ABTECT-2 – ABX464 Treatment Evaluation for ulcerative Colitis Therapy -2 Not authorised
  2022-500536-11-00 5 Moderately to severely active ulcerative colitis
• ABTECT-Maintenance – ABX464 Treatment Evaluation for ulcerative Colitis Therapy Not authorised
  2022-500537-84-00 5 Moderately to severely active ulcerative colitis
• A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc … Unknown
  2022-502779-40-99 5 Primary prevention of atherosclerotic cardiovascular disease (ASCVD)
• Crohn’s Head-to-Head Assessing Risankizumab Versus Guselkumab for One Year Pending
  2025-521590-13-00 5 Moderately to Severely Active Crohn’s Disease
• Efficacy and Safety of KAI-9531 in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes Pending
  2025-523486-17-00 5 Obesity
• Efficacy and Safety of KAI-9531 in Participants Living With Obesity or Overweight and Diabetes Pending
  2025-523510-87-00 5 Obesity
• A clinical study to evaluate the effects of RO7795068 in participants with obesity or overweight and type 2 diabetes Recruiting
  2025-523106-32-00 5 2026-05-25 Obesity or Overweight and Type 2 Diabetes
• A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin ( ENLIGHTEN-6 ) Recruiting
  2025-523659-73-00 5 2026-05-11 Obesity
• Vedolizumab Subcutaneous Long-term Open-label Extension Study in Pediatric Subjects Recruiting
  2023-508804-39-00 5 2025-10-15 Ulcerative Colitis or Crohn’s Disease
• A clinical study of MK-7240 for the treatment of Crohn’s disease (MK-7240-008) Recruiting
  2024-518296-56-00 5 2025-09-29 Crohn’s Disease
• Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obe … Recruiting
  2024-520209-38-00 5 2025-09-19 Obesity or Overweight
• Phase 3 Study of Vedolizumab Subcutaneous in Pediatric Subjects With Moderately to Severely Active Ulcerative Colitis or Crohn’s Disease Recruiting
  2023-503188-40-00 5 2025-01-06 Active Ulcerative Colitis or Crohn’s Disease
• Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects with Moderately to Severely Active Crohn's Dis … Recruiting
  2023-509618-12-00 5 2024-09-11 Crohn's Disease (CD)
• Crohn's Disease: Pharmacokinetics, Efficacy, and Safety of Risankizumab in Pediatric Subjects with Moderately to Severely Active Crohn's Dis … Recruiting
  2022-502050-14-00 5 2024-06-04 Crohn's disease
• AMAZE 5: A research study investigating how well the medicine NNC0487-0111 helps people with excess body weight and knee osteoarthritis lose … Recruiting
  2024-520444-42-00 5 2026-04-15 Overweight or obesity, and knee osteoarthritis
• AMAZE 6: A research study investigating how well the medicine NNC0487-0111 helps people with excess body weight and knee osteoarthritis lose … Recruiting
  2024-520445-23-00 5 2026-04-15 Overweight or obesity, and knee osteoarthritis
• A study to test how well PLENVU®, a bowel cleansing medicine, works in children and teenagers before they have a colonoscopy exam Recruiting
  2025-522046-42-00 5 2026-03-24 Colonic disease
• A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) Recruiting
  2025-522674-36-00 5 2026-03-24 Metabolic Dysfunction-Associated Steatotic Liver Disease
• A Study to Investigate Using Inhaled Fexlamose to Treat Adult Participants Who Have Moderate to Severe COPD Recruiting
  2025-523020-50-00 4 2026-03-04 Chronic Obstructive Pulmonary Disease
• A Phase 3, Randomized, Open-label, Multicenter Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System … Recruiting
  2024-519493-39-00 5 2025-12-09 High-risk Non-muscle-invasive Bladder Cancer with Susceptible FGFR Alt
• Efficacy and Safety of Icotrokinra in Adult and Adolescent Participants with Moderately to Severely Active Ulcerative Colitis Recruiting
  2025-521381-10-00 5 2025-12-03 Moderately to Severely Active Ulcerative Colitis
• Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants with Atherosclerotic Cardiovascular Disease and … Recruiting
  2024-516652-18-00 5 2025-10-10 Atherosclerotic cardiovascular disease (ASCVD) and obesity or overweig
• Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn’s Disease and Obesity or Overweight: … Recruiting
  2024-520210-21-00 5 2025-09-19 Crohn’s Disease
• A multicenter, open label, two cohort, single arm, phase II study to evaluate the efficacy and safety of the anti-TROP2 antibody-drug conjug … Recruiting
  2023-504898-20-00 4 2024-07-30 Thyroid neoplasms: ● Cohort 1: Advanced radioactive-iodine refractory

Showing 1–24 of 58 trials